Icariin ameliorates behavioral deficits and neuropathology in a mouse model of multiple sclerosis
Brain Research · 2023
DOI: 10.1016/j.brainres.2023.148267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2023. Verfasst von Dan Gao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing Engineering Research Center for Nervous System Drugs, Beijing 100053, …. Hauptthemen laut MEDLINE: Multiple Sclerosis, Encephalomyelitis, Autoimmune, Experimental, White Matter. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a systemic inflammatory illness of the central nervous system that involves demyelinating lesions in the myelin-rich white matter and pathology in the grey matter. Despite significant advancements in drug research for MS, the disease's complex pathophysiology makes it difficult to treat the progressive forms of the disease. In this study, we identified a natural flavonoid compound icariin (ICA) as a potent effective agent for MS in ameliorating the deterioration of symptoms including the neurological deficit score and the body weight in a murine experimental autoimmune encephalomyelitis (EAE) model. These improvements were associated with decreased demyelination in the corpus callosum and neuron loss in the hippocampus and cortex confirmed by immunohistochemistry analysis. Meanwhile, it was observed that the activation of microglia in cerebral cortex and hippocampus were inhibited followed by the neuroinflammatory cytokines downregulation such as IL-1β, IL-6 and TNF-α after ICA treatment, which was probably attributable to the suppression of microglial NLRP3 inflammasome activation. Additionally, molecular docking also revealed the binding force of ICA to NLRP3 inflammasome protein complexes in vitro. Taken together, our findings have demonstrated that ICA, as pleiotropic agent, prevents EAE-induced MS by improving demyelination and neuron loss, which interferes with the neuroinflammation via microglial NLRP3 inflammasome activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing Engineering Research Center for Nervous System Drugs, Beijing 100053, China.
- Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing Engineering Research Center for Nervous System Drugs, Beijing 100053, China. Electronic address: ycctmg@126.com.
- Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing Engineering Research Center for Nervous System Drugs, Beijing 100053, China; Phase I Clinical Trial Unit, Beijing Ditan Hospital Capital Med…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Gao, D., Zheng, C. C., Hao, J. P., Yang, C. C., & Hu, C. Y. (2023). Icariin ameliorates behavioral deficits and neuropathology in a mouse model of multiple sclerosis. Brain Research. https://doi.org/10.1016/j.brainres.2023.148267
Vancouver
Gao D, Zheng CC, Hao JP, Yang CC, Hu CY. Icariin ameliorates behavioral deficits and neuropathology in a mouse model of multiple sclerosis. Brain Research. 2023. doi:10.1016/j.brainres.2023.148267
BibTeX
@article{Gao2023,
author = {Gao, Dan and Zheng, Ceng-Ceng and Hao, Jin-Ping and Yang, Cui-Cui and Hu, Chao-Ying},
title = {Icariin ameliorates behavioral deficits and neuropathology in a mouse model of multiple sclerosis},
journal = {Brain Research},
year = {2023},
doi = {10.1016/j.brainres.2023.148267}
}
EUVIMED